000			01745 a2200505 4500
005			20250517183619.0
264		0	_c20180515
008			201805s 0 0 eng d
022			_a1879-114X
024	7		_a10.1016/j.clinthera.2017.09.016 _2doi
040			_aNLM _beng _cNLM
100	1		_aHeintjes, Edith M
245	0	0	_aFactors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries. _h[electronic resource]
260			_bClinical therapeutics _cNov 2017
300			_a2296-2310.e14 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aBody Mass Index
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aDipeptidyl-Peptidase IV Inhibitors _xtherapeutic use
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEurope
650	0	4	_aFemale
650	0	4	_aGlycated Hemoglobin _xanalysis
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xtherapeutic use
650	0	4	_aInsulin _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMetformin _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aSulfonylurea Compounds _xtherapeutic use
650	0	4	_aThiazolidinediones _xtherapeutic use
650	0	4	_aYoung Adult
650	0	4	_aGlucagon-Like Peptide-1 Receptor Agonists
700	1		_aOverbeek, Jetty A
700	1		_aHall, Gillian C
700	1		_aPrieto-Alhambra, Daniel
700	1		_aLapi, Francesco
700	1		_aHammar, Niklas
700	1		_aBezemer, Irene D
773	0		_tClinical therapeutics _gvol. 39 _gno. 11 _gp. 2296-2310.e14
856	4	0	_uhttps://doi.org/10.1016/j.clinthera.2017.09.016 _zAvailable from publisher's website
999			_c27759837 _d27759837